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Objective: Hepatocyte growth factor, a potent angiogenic agent, is unique in having
the effects of antiapoptosis and antifibrosis. In the present study we used the rapid
pacing–induced heart failure canine model to investigate the effect of gene trans-
fection of hepatocyte growth factor on the failing heart.
Methods: Four weeks after onset of rapid pacing, either the human hepatocyte
growth factor gene (160 g; hepatocyte growth factor group, n 7) or empty vector
(control group, n  7) was directly injected into the left ventricular myocardium by
means of the hemagglutinating virus of Japan liposome method.
Results: At 4 weeks after gene transfection, the left ventricular global function,
assessed by means of pressure-volume loop analysis, was improved in the hepato-
cyte growth factor group as preload-recruitable stroke work (percentage of baseline:
80%  20% from 38%  15% before gene transfection, P  .005), whereas it was
not changed in the control group (50%  18% from 50%  18%). Weekly
echocardiography showed that this improvement began in the week after gene
transfer. The hearts in the hepatocyte growth factor group had a large wall thickness,
large myocyte diameter, high capillary density, low fibrotic area fraction, and low
density of apoptotic nuclei revealed by means of histologic analysis compared with
that in the control group. Myocardial perfusion flow, assessed with color micro-
spheres, was increased in the hepatocyte growth factor group (percentage of base-
line: 79%  16% from 48%  14%, P  .010), whereas it was reduced in the
control group (30%  12% from 45%  17%).
Conclusions: Gene transfection of hepatocyte growth factor promoted angiogenesis,
improved perfusion, decreased fibrosis and apoptosis, promoted recovery from
myocyte atrophy, and thereby attenuated cardiac remodeling and improved myo-
cardial function in the failing heart. It is a novel gene therapy for human heart failure.
Hepatocyte growth factor (HGF) is a potent angiogenic agent1possessing mitogenic, motogenic, and morphogenic effectsthrough its own specific receptor, c-Met, in various types of cells,including myocytes.2 Recent studies revealed that HGF has ef-fects of antifibrosis and antiapoptosis in the myocardium.3,4 Con-sidering the pathologic characteristics of severe heart failure, such
as apoptosis-related loss of contractile mass,5 progression of fibrosis,6 progression
of endothelial dysfunction,7 and loss of functional capillaries,8 HGF might be
beneficial in the failing heart by attenuating these remodeling processes.
To test this hypothesis, we used the canine ventricular rapid pacing–induced
cardiomyopathy model and performed HGF gene transfer to failing myocardium by
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means of direct intramyocardial administration of hemag-
glutinating virus of Japan (HVJ) liposomes encoding human
HGF cDNA.
Methods
Animal Model and Experimental Protocol
Fourteen adult female beagles (8.0  1.0 kg) received ventricular
rapid pacing for 8 weeks. Care of the animals was in compliance
with the “Guide of the Care and Use of Laboratory Animals,”
prepared by the Institute of Laboratory Animal Resources in Osaka
University Medical School, and the “Guide of the Care and Use of
Laboratory Animals,” published by the National Institute of Health
(National Institute of Health publication no. 86-23, revised 1985).
Invasive evaluation was done 3 times: (1) at baseline (before onset
of rapid pacing); (2) before gene transfection (at 4 weeks after
onset of rapid pacing); and (3) after gene transfection (at 4 weeks
after gene transfection or 8 weeks after onset of rapid pacing). At
each time point, beagles were anesthetized with ketamine (8 mg/kg
administered intramuscularly) and pentobarbital (30 mg/kg admin-
istered intravenously), intubated, and ventilated (Ventilator 710;
Siemens-Elema AB, Solna, Sweden). Anesthesia was maintained
with inhalation of sevoflurane (2% vol/vol). A small thoracotomy
was performed through the fifth intercostal space in the right side
for baseline studies and in the left side for studies before and after
gene transfection. Implantation of pacemaker was done as follows.
Two pacemaker leads were fixed with surgical sutures on the right
ventricle free wall surface. A pulse generator (Thera; Medtronic,
Eden Prairie, Minn) was placed in a subcutaneous pocket anterior
to the right second rib. The pacemaker was programmed and
started after the operation at a rate of 240 pulses/min. A sonomi-
crometer crystal (WT-20; Crystal Biotech, Hopkinton, Mass) was
fixed with surgical sutures on the left ventricular (LV) free wall
surface for measurement of regional contractile function. A 7F
conductance catheter (Cordis Europe, Roden NA, The Nether-
lands) and a 5F micromanometer (MPC-500; Millar, Houston,
Tex) were inserted into the left ventricle from the apex to measure
LV pressure and volume. A flare-tipped catheter was inserted into
the left atrium for injection of microspheres. Another catheter was
inserted into the left femoral artery for microsphere reference
blood sampling. After completion of the evaluation, all 4 catheters
were removed; the pericardium and chest were closed. Weekly
echocardiography was performed after achievement of light anes-
thesia with ketamine (6 mg/kg administered intramuscularly). The
rate of pacemaker stimulation was reduced to 70 pulses/min at
DDD mode before each examination, so that the heart was eval-
uated at sinus rhythm.
Preparation of Vectors and Gene Transfection
Human HGF cDNA was inserted into the NotI site of the pUC-SRa
expression vector.9 HVJ liposome was prepared, as described
elsewhere.10 Four weeks after onset of rapid pacing, HVJ-HGF
liposomes (containing 160 g of HGF gene) or HVJ liposomes in
1 mL of N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid–
buffered saline solution were introduced into the myocardium by
means of direct intramyocardial injection with a 26-gauge needle.
Liposomes were injected randomly at 10 sites (10 0.1 mL) in the
LV free wall. Beagles received either the human HGF gene–
encoding vector in the HGF group (n  7) or empty vector in the
control group (n  7).
Blood and Tissue HGF Assay
Venous blood samples were collected daily. One animal in each
group was killed at 5 days after gene transfection, and the others
were killed at 4 weeks after gene transfection. Five myocardial
tissue samples were taken randomly from the LV free wall of each
heart, frozen immediately in liquid nitrogen, and stored at 80°C
until assay. The levels of human HGF protein in cardiac tissue and
plasma were measured by means of enzyme-linked immunosor-
bent assay with an anti-human HGF monoclonal antibody (Insti-
tute of Immunology, Tokyo, Japan), as described previously.11
Levels of human HGF mRNA in the myocardium were analyzed
by means of reverse transcription–polymerase chain reaction, as
described previously.12
Measurement of LV Function
We used a cardiac loop analysis computer system (Signal Proces-
sor 1000; NEC, Tokyo, Japan) with a volumetric system (Sigma 5;
Leycom, Oegstgeest, the Netherlands) to perform LV pressure-
volume loop analysis. Measurements and analyses were performed
as previously described.13 The preload-recruitable stroke work
(PRSW) and the end-systolic pressure-volume relation (ESPVR)
were calculated to represent LV global systolic function, and the
end-diastolic pressure-volume relation (EDPVR) was calculated to
represent LV global diastolic function. Regional myocardial func-
tion was measured with the epicardial crystal pulsed-Doppler
technique14 by using a sonomicrometer crystal. Dobutamine (20
g  kg1  min1) was infused intravenously for 10 minutes be-
fore recording the data. Thickness fraction (TF) was calculated as
previously described.15 Echocardiography was performed with an
ultrasonograph (SSA-260A; Toshiba Corp, Tokyo, Japan) with a
3.75-MHz transducer. Two-dimensional images of LV and M-
mode recordings were obtained for the measurement of posterior
wall thickness (PWTh), LV end-diastolic volume (EDV), and
ejection fraction (EF).
Evaluation of Regional Myocardial Perfusion
Regional myocardial perfusion was measured by using the colored
microsphere technique.16 Microspheres (15 m in diameter, 3 
106 spheres in each dose) were infused within 20 seconds, and
reference blood was withdrawn at a rate of 6 mL/min. Micro-
spheres in red, yellow, and blue were used for baseline studies and
studies before and after gene transfection. Myocardial perfusion
was measured at 5 randomly selected myocardial tissue samples in
each heart. Perfusion flow was calculated as a percentage of
baseline value.
Histologic Evaluation
The hearts were cut at short axis into several pieces at the end of
the experiment. LV wall thickness was directly measured at the
midpapillary muscle level at 10 sites in each heart. From frozen
tissue samples, myocardium was cut into 5-m-thick slices and
stained with the following, according to the manufacturer’s man-
ual. First, a rabbit polyclonal antibody against human factor VIII–
associated antigen (DAKO Corporation, Carpinteria, Calif), which
is a marker for endothelial cells, was used for vessel staining.
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Second, an in situ apoptosis detection kit (Apoptag) was used in
the terminal deoxynucleotidyl transferase mediated dUTP nick-
end labeling (TUNEL) for apoptosis. Third, elastica Van-Gieson
staining of collagen was used to examine the fibrosis. Fourth,
hematoxylin and eosin staining was performed. Computer (Mac-
Scope v 2.5.1; Mitani Corp, Tokyo, Japan) appraisal of pathology
(vascular density, percentage of amount of TUNEL-positive nuclei,
fibrotic area fraction, and myocyte diameter) was performed on 10
randomly chosen optical fields (0.56 mm2) of each heart. A patholo-
gist who was blind to treatment carried out histologic evaluation.
Statistical Analysis
All values are expressed as means  SD. Comparisons (PWTh,
EDV, and EF) were performed by using 1-way analysis of vari-
ance, followed by the Bonferroni least-significant-difference test.
Others (cardiac functional indices and histologic data) were com-
pared by using the Student t test.
Results
Efficiency of Gene Transfection
Protein and mRNA of human HGF were detected in the LV
myocardium at 5 days after gene transfection in the HGF
group only (0.17 ng of protein in 1 g of tissue wet weight),
whereas they were not detected in the control group (Figure
1). Neither was detected in either group at 4 weeks after
gene transfection. There was no detectable (0.01 ng)
human HGF in blood throughout the experiment.
HGF Promotes Recovery of Myocytes From Atrophy
The PWTh, determined on the basis of echocardiography,
was significantly increased in the HGF group (6.6  1.1
mm from 3.9 1.0 mm before gene transfection, P .001),
whereas it was not changed in the control group (4.7  0.5
mm from 4.7 0.8 mm before gene transfection, P .826).
EDV was slightly reduced in the HGF group (41.4  7.3
mL from 50.4  9.1 mL before gene transfection, P 
.088), whereas it was significantly increased in the control
group (59.4  9.1 mL from 46.9  7.7 mL before gene
transfection, P  .027, Figure 2). The gross anatomy
showed that the LV wall thickness, by means of direct
measurement, was significantly higher in the HGF group
(9.8  2.1 mm, P  .020) than in the control group (7.1 
0.7 mm). The myocyte diameter was significantly greater in
the HGF group (33  4 m, P  .0001) than in the control
group (23  4 m; Figure 3, A).
HGF Promotes Angiogenesis and Perfusion
The capillary density was significantly higher in the HGF
group (1667  531/mm2, P  .011) than in the control
Figure 1. HGF mRNA expression in the LV myocardium at 5 days
after gene transfection by means of reverse transcription–poly-
merase chain reaction of human HGF. A high level of HGF mRNA
was observed in the heart receiving the HGF gene vector but not
in the heart receiving the empty vector (control). Molecular size
markers are shown in the left margin.
Figure 2. Echocardiographic findings. The PWTh and EF were
improved, and EDV was reduced soon after transfection in the
HGF group. Data are expressed as means SEM. *P < .05 versus
the control group.
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group (811  360/mm2; Figure 3, B). Perfusion flow (per-
centage of baseline) was significantly improved in the HGF
group (78.9%  15.5% from 47.8%  13.7% before gene
transfection, P  .010), whereas it was slightly reduced in
the control group (30.7%  12.6% from 44.9%  16.9%
before gene transfection, P  .128).
Figure 3. Histopathology of LV myocardium. A, Hematoxylin and eosin–stained tissue sections (bar  50 m). The
myocyte diameter is higher in the HGF group than in the control group. B, Sections were stained with antibody
against factor VIII and counterstained with eosin (bar 50 m). The vessel density is higher in the HGF group than
in the control group. C, Sections were stained with TUNEL and counterstained with eosin (bar  50 m). High
magnification shows TUNEL-positive myocytes (arrow). The number of TUNEL-positive cells is lower in the HGF
group than in the control group. D, Sections with Van Gieson staining of collagen and eosin counterstaining (bar
100 m). The fibrotic area is smaller in the HGF group than in the control group.
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HGF Inhibits Apoptosis and Fibrosis
The percentage of TUNEL-positive myocytes was signifi-
cantly lower in the HGF group (0.4%  0.4%, P  .049)
than in the control group (1.5%  1.0%; Figure 3, C). The
percentage area of fibrosis was also significantly less in the
HGF group (0.6%  0.2%, P  .0002) than in the control
group (2.0%  0.6%; Figure 3, D).
HGF Improves LV Contractile Function
The EF, determined on the basis of echocardiography, was
slightly increased in the HGF group (46.4%  5.6% from
38.8% 7.9% before gene transfection, P .083), whereas
it was significantly reduced in the control group (25.3% 
7.5% from 39.0%  6.3% before gene transfection, P 
.006, Figure 2). Table 1 shows the LV systolic and diastolic
functions before and after gene transfection. A good recov-
ery of PRSW and ESPVR was observed in the HGF group,
with the values significantly better than those before gene
transfection. Values after gene transfection of EDPVR, a
measurement of LV diastolic function, were significantly
better in the HGF group than in the control group. The TF,
either at rest or under dobutamine stress, was significantly
improved in the HGF group, whereas it was not changed in
the control group.
Discussion
The present study has demonstrated that HGF gene trans-
fection improves the LV function in a canine model of rapid
pacing–induced cardiomyopathy. This improvement was
associated with promoted myocardial recovery from atro-
phy, increased myocardial collateral-vessel development
and perfusion, and reduced myocardial fibrosis and apopto-
sis.
Considering the gene therapy in a future clinical trial,
only the patients with symptoms of severe heart failure can
be candidates. Therefore this study was designed to perform
the gene transfer of HGF at 4 weeks after onset of rapid
pacing, when those hearts showed a marked pathologic
change of cardiomyopathy with significant deterioration of
cardiac function similar to the characteristics of cardiomy-
opathy.
As opposed to conventional therapies that focus on alle-
viating the symptoms of heart failure, the concept for the
use of HGF is to attenuate pathologic remodeling of heart
failure. By promoting angiogenesis, attenuating apoptosis
and fibrosis, and promoting the myocyte recovery from
atrophy in the failing myocardium, this new concept is an
attempt to preserve and increase the contractile mass, re-
shape the ventricular geometry, improve myocardial perfu-
sion, and change interstitial collagen composition. These
methods have been proved to be functionally advantageous.
We used 3 independent methods to measure cardiac
function. EF from echocardiography, TF from epicardial
crystal pulse-Doppler technique, and PRSW, ESPVR, and
EDPVR from pressure-volume loop analysis indicated the
same result: HGF gene transfection can improve cardiac
function in the failing heart. PRSW, ESPVR, and EDPVR
have been proposed as a load-independent index of contrac-
tile function17 and were used as the gold standard of LV
function. The crystal was fixed on the LV surface and
measured at the same place throughout the experiment. As
a result, our conclusion is correct and reliable.
TABLE 1. Indices of LV function
Control
P value*
HGF
P value* P value†Baseline Pregene Postgene Baseline Pregene Postgene
Systolic function
PRSW
Slope (1000 erg/mL) 83.2 5.6 40.9 13.7 41.9 15.8 .908 81.2 5.9 30.3 9.7 64.9 17.0 .004 .045
% of baseline 49.6 18.1 49.9 17.7 .974 37.8 14.6 80.0 20.0 .005 .026
ESPVR
Slope (mm Hg/mL) 9.7 1.9 4.9 2.4 6.3 1.7 .260 9.5 1.7 4.5 2.5 9.2 1.2 .004 .010
% of baseline 49.6 18.6 66.4 16.9 .132 45.4 20.3 98.5 16.6 .001 .011
Diastolic function
EDPVR
Slope (102 mm Hg/mL) 83.4 12.5 143.0 52.4 211.5 47.4 .038 87.7 11.7 147.6 45.2 116.4 22.7 .204 .002
% of baseline 168.1 42.6 252.9 44.4 .007 169.6 52.0 131.8 9.5 .148 .0002
Regional function
TF (%)
Rest 18.0 2.2 7.1 1.8 6.3 1.8 .515 18.0 2.2 6.2 2.8 10.2 3.2 .029 .032
Stress 25.0 8.5 6.8 2.7 7.7 1.9 .521 27.3 6.0 7.5 2.9 13.6 3.5 .017 .005
Data are expressed as mean  SD. Pregene, Before gene transfection; Postgene, after gene transfection.
*Postgene versus Pregene within group.
†Postgene versus Postgene between groups.
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The findings on LV wall thickness, volume, and myocyte
diameter indicated that HGF promotes myocardial recovery
from atrophy and reshaped the ventricular geometry in the
canine cardiomyopathy model. The underlying mechanism
of this effect is probably that through c-Met, a transmem-
brane tyrosine kinase, HGF activates the Ras-Raf-MEK-
ERK signaling pathway, which is implicated in myocardial
hypertrophy.18,19 Because of the danger of myocardial bi-
opsy, we did not have any histologic information of the
heart before gene transfection. However, on the basis of
histologic findings from our previous canine model studies,
we concluded that myocyte diameter was recovered to a
normal level from atrophy. The absence of HGF at 4 weeks
after gene transfection indicated that the preservation of this
recovery seems not to depend on HGF supply for at least
several weeks. The future of this recovery is still unknown.
The myocardial vasculature is an obligatory determinant
of the ventricular remodeling.20 Coronary perfusion is de-
creased in failing myocardium as a result of fibrosis and
structural changes in the capillary network.8 The findings in
capillary density and myocardial perfusion indicated that
HGF promotes angiogenesis in the failing myocardium. The
most important point is that those new capillaries were
functional to increase myocardial perfusion. Concerning the
regional perfusion flow, previous experiments showed that
there is tremendous animal-to-animal variability at all levels
of the myocardium. We found a large variation of actual
perfusion flow (approximately 0.6-3.9 mL  min1  g1) in
different parts of same heart and the same parts of different
hearts. Only the rates of change are equal in most parts of
the heart.
Myocyte loss occurs through apoptosis in chronic heart
failure. HGF has an antiapoptotic effect, likely through the
activation of the phosphatidylinositol-3-OH kinase path-
way.4,21 The findings in the TUNEL staining of apoptosis
indicated that HGF prevented the myocardial apoptosis and
thereby preserved the LV contractile mass. This conclusion
was based on careful identification of every apoptotic cell in
the examined myocardial sections. Because apoptotic cells
are degraded within 1 to 2 weeks, the apoptotic cell numbers
would be lower in the week after HGF gene transfection.
The mechanism underlying the antifibrotic effect of HGF
is probably related to the activation of matrix metallopro-
teinases, the inhibition of collagen formation, and the inhi-
bition of transforming growth factor  secretion.22 The
findings in the fibrotic area fraction indicated that HGF
prevented the remodeling on myocardial collagen. Less
fibrosis in the myocardium is beneficial in improving the
contractile function and angiogenesis of failing myocar-
dium.
Previous studies reported the beneficial effects of insu-
lin-like growth factor or growth hormone therapy in animal
models of heart failure.23,24 However, their effects in pa-
tients with heart failure are still controversial.25 Promotion
of myocardial hypertrophy and attenuation of apoptosis
only by insulin-like growth factor or growth hormone ther-
apy or promotion of angiogenesis only by vascular endo-
thelial growth factor or fibroblast growth factor therapy are
likely not to be sufficient to attenuate cardiac remodeling in
heart failure. Therefore HGF might be the most promising
agent for heart failure therapy among the growth factor
family.
This study, for the first time, showed the effectiveness of
HGF gene therapy in heart failure by functional and patho-
logic evidence but leaves several unresolved issues. First,
because of the limitations of experimental space and financ-
ing, there is no mechanism study. We expect this will be
clarified in the near future in small animal models. Second,
because of a lack of measurement techniques for canine
HGF, changes and roles of endogenous HGF in this model
are not clear. Third, the long-term outcome of those effects
of HGF is not clear. Fourth, this dose came from a previous
gene dose/HGF protein expression ratio study in canine
heart by means of direct injection. There was no dose-
response study in this model. Other alternative routes will
be studied in the near future.
Because of some similarities between this canine exper-
imental model and human cardiomyopathy,26 the results of
this study provide preliminary evidence that HGF gene
transfection might provide a therapeutic method for treat-
ment of human heart failure. If future studies using gene
therapy with HGF in patients with end-stage heart disease
demonstrate a beneficial effect on mortality and morbidity,
this new therapeutic approach might become an attractive
alternative to cardiac transplantation or became a bridge to
transplantation in these patients.
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